Galmed Pharmaceuticals (GLMD) Other Non Operating Income (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Other Non Operating Income of -$495000.0 for Q4 2025, down 1550.0% year-over-year from $34137.9 in Q4 2024, and down 343.84% quarter-over-quarter from $203000.0 in Q3 2025.
Galmed Pharmaceuticals (GLMD) Other Non Operating Income (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Other Non Operating Income history runs 10 years deep, the most recent figure standing at -$495000.0 for Q4 2025.
- In Q4 2025, Other Non Operating Income fell 1550.0% year-over-year to -$495000.0; the TTM figure through Dec 2025 stood at -$182000.0 (down 140.62% YoY), while the FY2025 annual figure was $741000.0, up 43.6% from the prior year.
- Other Non Operating Income for Q4 2025 stood at -$495000.0, down from $203000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $278000.0 in Q2 2023, with the low at -$495000.0 in Q4 2025.
- The 5-year median for Other Non Operating Income is $16000.0 (2021), against an average of $29000.0.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income surged 7050.0% in 2023, then plunged 1550.0% in 2025.
- Galmed Pharmaceuticals' Other Non Operating Income stood at $16000.0 in 2021, then tumbled by 125.0% to -$4000.0 in 2022, then soared by 7050.0% to $278000.0 in 2023, then slumped by 110.79% to -$30000.0 in 2024, then slumped by 1550.0% to -$495000.0 in 2025.
- Business Quant data shows GLMD's Other Non Operating Income at -$495000.0 in Q4 2025, $203000.0 in Q3 2025, and $140000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134,000.00 |
| Dec 31, 2025 | -495,000.00 |
| Sep 30, 2025 | 203,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Jun 30, 2024 | 103,000.00 |
| Jun 30, 2023 | 278,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Jun 30, 2021 | 16,000.00 |
| Jun 30, 2020 | 290,000.00 |
| Jun 30, 2019 | 532,000.00 |
| Jun 30, 2018 | 90,000.00 |
| Mar 31, 2014 | 10,000.00 |
| Mar 31, 2013 | 10,000.00 |